Skip to main content
INMB
NASDAQ Life Sciences

Inmune Bio Reports Statistically Significant Positive Phase 2 Alzheimer's Trial Results for XPro1595

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.42
Mkt Cap
$37.751M
52W Low
$1.09
52W High
$11.64
52W Position info
30% above low
Off High info
88% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

INMB sits 30% above its 52-week low of $1.09 on elevated volume (2.4× avg).

Summary

Inmune Bio announced statistically significant positive results from its Phase 2 MINDFuL trial for XPro1595 in early Alzheimer's disease, demonstrating a treatment effect on white matter biomarkers.


Key Events · Product Development and Regulatory · INMB

  • Positive Phase 2 Clinical Trial Results

    XPro1595 showed a statistically significant treatment effect on myelin in the full mITT population (p=0.0028) of the MINDFuL Phase 2 trial for early Alzheimer's disease.

  • Validation of Precision Medicine Approach

    Efficacy was further strengthened in biomarker-enriched patients with elevated inflammation (p=0.0098), validating the company's precision-medicine strategy for its Phase 2b/3 registrational program.

  • De-risked Regulatory Pathway

    The positive results follow FDA Fast Track designation and End-of-Phase 2 alignment for an integrated Phase 2b/3 seamless adaptive trial, providing a clear path toward commercial submission.

  • Addresses Going Concern Warning

    This critical positive data provides a strong scientific foundation for continued development and potential future financing, directly addressing the company's previously disclosed 'going concern' warning.


Analysis · INMB · Life Sciences

This filing announces statistically significant positive results from the Phase 2 MINDFuL clinical trial of XPro1595 in early Alzheimer's disease. The data, showing a treatment effect on white matter biomarkers, is critical for Inmune Bio, especially given its recent 'going concern' warning. Positive clinical data provides a strong scientific foundation for continued development and is essential for attracting future financing, directly addressing the company's liquidity concerns and de-risking its path forward. The FDA Fast Track designation and regulatory alignment for a seamless Phase 2b/3 registrational program further enhance the significance of these results.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INMB was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.8M. The 52-week trading range was $1.09 to $11.64. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INMB - Latest Insights

INMB
Nov 05, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $0.827 info
Change: -$0.348 (-30%) info
Market Cap: $25.603M info
INMB
Oct 29, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.827 info
Change: -$0.693 (-46%) info
Market Cap: $25.603M info
INMB
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.827 info
Change: -$0.583 (-41%) info
Market Cap: $25.603M info
INMB
Oct 21, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $0.827 info
Change: -$0.862 (-51%) info
Market Cap: $25.603M info
INMB
Oct 21, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.827 info
Change: -$0.803 (-49%) info
Market Cap: $25.603M info